Volume 23, No 1, Jan 2013

ISSN: 1001-0602 
EISSN: 1748-7838 2018 
impact factor 17.848* 
(Clarivate Analytics, 2019)

Volume 23 Issue 1, January 2013: 13-14

RESEARCH HIGHLIGHTS

Resistance to EGFR blockade in colorectal cancer: liquid biopsies and latent subclones

David J Konieczkowski^1,2 and Levi A Garraway^1,2,3

¹Broad Institute of Harvard and the Massachusetts Institute of Technology, 7 Cambridge Center, Cambridge, MA 02142, USA
>²Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Avenue, Boston, MA 02215, USA
³Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA Correspondence: Levi A Garraway(levi_garraway@dfci.harvard.edu)

Two recent papers identify KRAS activation as a mechanism of acquired resistance to EGFR blockade in colorectal cancer. In doing so, they suggest that resistance to single-agent EGFR blockade will be unavoidable because these alterations exist as latent subclones within the tumor even prior to the initiation of therapy.

Cell Research (2013) 23:13-14. doi:10.1038/cr.2012.115; published online 31 July 2012

FULL TEXT | PDF

Browse 5066